CD200 and acute myeloid leukemia: In particular, the understanding of each AML-MRC subtype may affect treatment decision, and the therapeutic approach using the novel agent CPX−351 could be prioritized over conventional chemotherapy for medically fit patients with AML-MRC-C and AML-MRC-H.